It is May 9 thru the 12th in Brussels (ICH). I think it's likely that preclinical data will have an impact on whether a thorough QT prolongation study ever gets done on a new drug. It all depends on whether a pharma is willing to dump a drug based on preclinical data that shows QT prolongation or not. I would think that preclinical studies also would be alot cheaper than a thorough QT study so I would imagine that these will be routinely done first. The crucial point really is what to do with a drug which shows preclinical QT prolongation in terms of clinical trials. If ERES were smart they'd get into the preclinical study business and bundle that with the thorough QT studies to offer the complete package. All of this is speculation on my part. I'm neither long or short right now.